Compare DexCom, Inc. (DXCM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs TransMedics Group Inc — how do they compare? DexCom, Inc. trades at $83.36 (market cap $31.86B), while TransMedics Group Inc trades at $77.5 (market cap $2.74B). The key difference: DexCom, Inc. is far larger — about 11.6× TransMedics Group Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and TransMedics Group Inc for 24 Days on average.
| DXCM | TMDX | |
|---|---|---|
Market Cap | $31.86B | $2.74B |
Volume | 3,607,070 | 949,331 |
Sector | Health | Health |
52-Week High | $92.34 | $150.42 |
52-Week Low | $54.84 | $61.99 |
Typical Hold Time | 62 Days | 24 Days |
Enterprise Value | $31.32B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
